99 related articles for article (PubMed ID: 32877254)
1. Estradiol softgel inserts for the treatment of VVA symptoms: an expert opinion.
Liu JH; Bernick B; Mirkin S
Expert Opin Drug Deliv; 2020 Nov; 17(11):1573-1581. PubMed ID: 32877254
[TBL] [Abstract][Full Text] [Related]
2. Systemic estradiol levels with low-dose vaginal estrogens.
Santen RJ; Mirkin S; Bernick B; Constantine GD
Menopause; 2020 Mar; 27(3):361-370. PubMed ID: 31794498
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the effect of noninvasive radiofrequency with vaginal estrogen and vaginal moisturizer in the treatment of vulvovaginal atrophy in postmenopausal women: a randomized clinical trial.
Gueldini de Moraes AV; Costa-Paiva L; da Costa Machado H; Maciel TF; Mariano FV; Pedro AO
Menopause; 2024 Apr; 31(4):288-302. PubMed ID: 38412393
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of non-ablative CO
Lami A; Alvisi S; Baldassarre M; Zanella S; Amati V; Seracchioli R; Meriggiola MC
Arch Gynecol Obstet; 2024 Apr; 309(4):1575-1583. PubMed ID: 38253692
[TBL] [Abstract][Full Text] [Related]
5. Vaginal laser therapy for GSM/VVA: where we stand now - a review by the EUGA Working Group on Laser.
Salvatore S; Ruffolo AF; Phillips C; Athanasiou S; Cardozo L; Serati M;
Climacteric; 2023 Aug; 26(4):336-352. PubMed ID: 37395104
[TBL] [Abstract][Full Text] [Related]
6. Treating dyspareunia caused by vaginal atrophy: a review of treatment options using vaginal estrogen therapy.
Kingsberg S; Kellogg S; Krychman M
Int J Womens Health; 2010 Aug; 1():105-11. PubMed ID: 21072280
[TBL] [Abstract][Full Text] [Related]
7. Relationships between the vaginal microbiota and genitourinary syndrome of menopause symptoms in postmenopausal women: the Study of Women's Health Across the Nation.
Waetjen LE; Crawford SL; Gajer P; Brooks MM; Gold EB; Reed BD; Hess R; Ravel J
Menopause; 2023 Nov; 30(11):1073-1084. PubMed ID: 37788422
[TBL] [Abstract][Full Text] [Related]
8. An effective non-hormonal option with high tolerability for mild to moderate symptoms of vaginal dryness associated with menopause.
Eichler S; Panz M; Harder A; Masur C; Häuser M; Wiesche ESZ
Maturitas; 2024 Jul; 185():107978. PubMed ID: 38583316
[TBL] [Abstract][Full Text] [Related]
9. Safety and Serum Estradiol Levels in Hormonal Treatments for Vulvovaginal Atrophy in Breast Cancer Survivors: A Systematic Review and Meta-Analysis.
Comini ACM; Carvalho BM; Moreira MJB; Reis PCA; Colapietro L; Northern J; Batalini F
Clin Breast Cancer; 2023 Dec; 23(8):835-846. PubMed ID: 37806915
[TBL] [Abstract][Full Text] [Related]
10. Injection Treatments for Vulvovaginal Atrophy of Menopause: A Systematic Review.
Moccia F; Pentangelo P; Ceccaroni A; Raffone A; Losco L; Alfano C
Aesthetic Plast Surg; 2023 Dec; 47(6):2788-2799. PubMed ID: 37580562
[TBL] [Abstract][Full Text] [Related]
11. Study of Vulvovaginal Atrophy and Genitourinary Syndrome of Menopause and Its Impact on the Quality of Life of Postmenopausal Women in Central India.
Ulhe SC; Acharya N; Vats A; Singh A
Cureus; 2024 Feb; 16(2):e54802. PubMed ID: 38529421
[TBL] [Abstract][Full Text] [Related]
12. Prospective, multicenter, uncontrolled study on the effectiveness and safety of a hyaluronic acid water-based vaginal lubricant in alleviating vaginal dryness and dyspareunia.
Sánchez-Prieto M; Pingarrón C; Bergamaschi L; Bermúdez JC; Subiris González J; Sánchez Sánchez R; Poyo Torcal S; Gómez M; Ruiz Pérez ML; Castillo Martínez M; Peña Penedo ME; Sánchez-Borrego R
Gynecol Endocrinol; 2024 Mar; 40(1):2317268. PubMed ID: 38468593
[TBL] [Abstract][Full Text] [Related]
13. The effects of a real-time temperature monitoring non-ablative monopolar radiofrequency technology on vulvovaginal atrophy symptoms in postmenopausal Chinese women.
Cheng V; Chi-Shing WT; Lee A; Lee R
J Cosmet Dermatol; 2024 Jun; 23(6):2030-2043. PubMed ID: 38450826
[TBL] [Abstract][Full Text] [Related]
14. Vulvovaginal atrophy in the CRETA study: the healthcare professionals' perception.
Cancelo MJ; Sánchez Borrego R; Palacios S; Baquedano L; Corbacho Garza T; Fernández Aller N; García Ferreiro C; Quijano Martín JJ; González Calvo AJ
Gynecol Endocrinol; 2023 Dec; 39(1):2264405. PubMed ID: 37811796
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of a Diode Vaginal Laser in the Treatment of the Genitourinary Syndrome of Menopause.
Barba M; Cola A; De Vicari D; Costa C; Castelli AP; Volontè S; Fruscio R; Frigerio M
Bioengineering (Basel); 2023 Oct; 10(10):. PubMed ID: 37892888
[TBL] [Abstract][Full Text] [Related]
16. Ospemifene for vulvar and vaginal atrophy: an overview.
Palacios S
Drugs Context; 2020; 9():. PubMed ID: 32670378
[TBL] [Abstract][Full Text] [Related]
17. Oral lasofoxifene's effects on moderate to severe vaginal atrophy in postmenopausal women: two phase 3, randomized, controlled trials.
Kagan R; Simon JA; Goldstein SR; Komm BS; Jenkins SN; Portman DJ
Menopause; 2024 Jun; 31(6):494-504. PubMed ID: 38652875
[TBL] [Abstract][Full Text] [Related]
18. Microablative fractional radiofrequency for sexual dysfunction and vaginal Trophism: A randomized clinical trial.
Sarmento ACA; Fernandes FS; Maia RR; de Araújo Santos Camargo JD; de Oliveira Crispim JC; Eleutério Júnior J; Gonçalves AK
Clinics (Sao Paulo); 2023; 78():100293. PubMed ID: 37839177
[TBL] [Abstract][Full Text] [Related]
19. Female sexual dysfunction and lower urinary tract symptoms associated with vulvovaginal atrophy symptoms: Results of the GENJA study.
Ozaki Y; Tomoe H; Shimomura M; Ninomiya N; Sekiguchi Y; Sato Y; Nagao K; Takahashi Y; Takahashi S
Int J Urol; 2023 Oct; 30(10):860-865. PubMed ID: 37287405
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
